mobile menu toggle

What we do here
changes lives everywhere.

Follow the science:

Understanding how cancer hijacks the body’s oxygen-sensing system leads to new therapies for kidney cancer, heart disease and more.

Identifying the EGFR mutation leads to the first broad application of precision medicine in lung cancer – which is paving the way for other active targeted lung cancer therapies.

Combining treatments of the PD-L1 and CTLA-4 pathways creates a “double assault” that is effective for melanoma, kidney and other cancers.

Identifying BCL-2 as a protein cancer cells use to prevent self-destruction leads to the BCL-2 inhibitor venetoclax, which has become a powerful agent in the fight against CLL and AML.

Dana-Farber shares patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.

One advanced cancer discovery after another for 75 years.

Immunotherapy combination shows significant benefit for patients with advanced melanoma

A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. The trial, known as the RELATIVITY-047 study was co-led by Dana-Farber Cancer...

Learn more >

FDA approval offers hope for prevention of acute graft-versus-host disease

Approval of the drug abatacept opens up bone marrow transplant as an option for many more patients with cancer or blood disorders — especially patients of diverse ethnicities, who have extra difficulty finding a good match The U.S. Food and Drug Administration (FDA) today approved a treatment...

Learn more >

Targeted drug combination shows unprecedented activity in some highly aggressive brain tumors

Treatment with dabrafenib and trametinib yielded encouraging rate of durable responses in both high-grade and low-grade brain tumors carrying the rare BRAF v600E mutation Study is first to show benefit of any targeted drugs in glioblastomas – the most aggressive brain tumor Routine testing for BRAF...

Learn more >

Venetoclax shown to benefit patients with Waldenström Macroglobulinemia, including some who relapsed after previous therapy

Drug represents a highly effective and safe oral based treatment approach for Waldenström macroglobulinemia, study leaders say. A drug that strips cancer cells of their quest for immortality represents an effective new option for patients with Waldenström macroglobulinemia, including those not...

Learn more >

Dana-Farber research supports FDA approval of immunotherapy drug given after surgery for certain patients with kidney cancer

Pembrolizumab is the first drug approved as adjuvant therapy for patients with kidney cancer considered at high risk of relapse An immunotherapy drug given as a treatment following kidney cancer surgery, whose clinical testing was led by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, becomes...

Learn more >

First FDA approval of CAR T-cell therapy for multiple myeloma marks milestone for patients

Approval of ide-cel for adults who have relapsed after four or more prior lines of therapy follows clinical trials led by Dana-Farber Cancer Institute investigators The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma,...

Learn more >

  • Twitter logo
  • Pinterest logo
  • Facebook logo
  • LinkedIn logo
  • YouTube logo
  • Instagram logo
Best Children's Hospitals Award from US News
Best Hospitals Award from US News
Harvard Medical School
Magnet Recognized
NCI
NCCN
Dana-Farber building